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L E T T E R  T O  T H E  E D I T O R
Mitochondrial ataxia is genetically and phenotypically 
heterogeneous
Dear Editor,
With interest, we read the article by Dong et al about the genetic 
cause of ataxia in 33 Chinese patients.1 The included patients were 
investigated by next‐generation sequencing (NGS) for a possible ge‐
netic cause of the clinical presentation.1 The study raises a number 
of comments and concerns.
We do not agree with the initial statement of the introduction 
that “ataxia is a heterogeneous group of disorders with multiple 
types…” Ataxia is a sign and found on clinical neurological exam‐
ination. If the authors mean hereditary ataxias, the wording needs 
to be adapted. A major group of hereditary ataxias was not men‐
tioned in the statement about the genetic classification of ataxias, 
and these are the maternally transmitted ataxias /mitochondrial 
ataxias).2
Ataxia may not only be a phenotypic manifestation of myoclonic 
epilepsy with ragged‐red fibers (MERRF), Kearns‐Sayre syndrome 
(KSS), neuropathy, ataxia, retinitis pigmentosa (NARP), or POLG1‐
associated mitochondrial disorders (MIDs), but may also occur in 
ponto‐cerebellar hypoplasia (PCH6), leukoencephalopathy with 
brainstem and spinal cord involvement (LBSL), X‐linked sideroblastic 
anemia (XLSA), mitochondrial recessive ataxia syndrome (MIRAS), 
in patients carrying the mutations m.3243A > G and in a number of 
other specific or nonspecific MIDs.3 Cerebellar ataxia may be also as‐
sociated with mutations in genes affecting mitochondrial functions, 
such as the L2HGDH,4 PITRM1,5 COA7,6 VPS13D,7 ACO2,8 NADK2,9 
VARS2,10 AIFM1,11 and SLC25A46,12 to mention just the ones most 
recently detected.
Ataxia may not only be due to cerebral causes but also due to 
abnormalities of the spinal cord or the peripheral nerves.13 Thus, it 
is conceivable that among the 33 included patients some had a spi‐
nal cord lesion or a sensory or sensorimotor neuropathy. Was ataxia 
among the 33 included patients classified according to the location 
of the lesion? Another indicator for sensory ataxia in the cohort 
studied is that 18% had sensory disturbances and 6% had autonomic 
dysfunction, which is frequently associated with sensory neuropa‐
thy. The authors excluded only some causes of acquired and hered‐
itary neuropathy but many more need to be excluded. How many 
of the 33 included patients presented with sensory or sensorimotor 
neuropathy? Exclusion of polyneuropathy as the cause of ataxia is 
particularly important as 18% of the 33 patients had clumsiness of 
their hands.
A further shortcoming of the report is the lack of a detailed 
family history. As the study looked for hereditary diseases, it is im‐
portant to look thoroughly for nonneurological and neurological 
abnormalities in addition to ataxia in any of the first‐degree rela‐
tives of the 33 included patients. This is particularly important as 
the genotype‐phenotype correlation may not be strong in each type 
of genetic defect, particularly in heteroplasmic mtDNA mutations, 
and as there may be significant phenotypic heterogeneity between 
first‐degree family members. Different phenotypes within a family 
can be due to the same mutation, why a genetic link between family 
members can be easily overlooked.
As spinocerebellar ataxias (SCAs) may be due to mutations in 
more than the 46 genes tested with the panel, it is important that 
particularly in the 28 patients in whom no genetic cause for ataxia 
could be detected by genetic screening, SCA is excluded.
Despite clinical manifestations in some of the first‐degree rela‐
tives of the five patients in whom a genetic cause of ataxia could be 
detected, only to one of these relatives was a genetic investigation 
proposed. However, genetic testing of all relatives is important to as‐
sess the type of transmission, to determine the degree of phenotypic 
heterogeneity and to determine whether the variant was inherited 
or sporadic.
Finally, we do not agree with the statement that there is no gold 
standard for assessing the pathogenicity of a mutation.1 At least for 
tRNA variants, the pathogenicity can be easily assessed by applica‐
tion of the modified Yarham score.14 The strength of the genotype‐
phenotype correlation can be assessed by application of the Smith 
score.14
Overall, this interesting study could be more meaningful by tak‐
ing a thorough family history from each of the participants, by exclu‐
sion of sensory ataxia, by genetic workup in all first‐degree relatives, 
and by exclusion of all possible differentials among those who did 
not carry a mutation in any of the targeted genes.
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